Nectin-4 (via BT8009)
E1266366
UNEXPLORED
Nectin-4 (via BT8009) is a cell-adhesion protein overexpressed on certain cancer cells and exploited as a tumor-associated antigen for targeted cancer therapy.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Nectin-4 (via BT8009) canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T17377777 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Nectin-4 (via BT8009) Context triple: [Bicycle Therapeutics, targets, Nectin-4 (via BT8009)]
-
A.
TAK-079
TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
-
B.
CNK4
CNK4 is the ICAO airport code assigned to Parry Sound Area Municipal Airport in Ontario, Canada.
-
C.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
D.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
E.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Nectin-4 (via BT8009) Target entity description: Nectin-4 (via BT8009) is a cell-adhesion protein overexpressed on certain cancer cells and exploited as a tumor-associated antigen for targeted cancer therapy.
-
A.
TAK-079
TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
-
B.
CNK4
CNK4 is the ICAO airport code assigned to Parry Sound Area Municipal Airport in Ontario, Canada.
-
C.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
D.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
E.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.